



DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

BEROMUN® 1mg, Powder for solution for infusion (Tasonermin- EU license number: EU/1/99/097/001):

Interim Supply of German Stock to Mitigate Supply Disruption

Dear Healthcare Professional,

To ensure continuity in supply, Belpharma s.a. has obtained approval from the MHRA to supply German product (batch number 96285; 1 pack) which is expected to be on the UK market from June 2026 to September 2026.

Please note the following:

- This product is considered licensed in the UK.
- The product from Germany has the same formulation as the UK product
- The product from Germany is manufactured according to the same manufacturing process and quality controls as the UK product.
- There are no differences between the German and UK product information.
- A multilingual leaflet, including English, is provided with the pack. For additional copies of the leaflet, please contact the company contact point (see below).
- The MHRA has agreed to an exemption granted in accordance with regulation 266(4)(a) and (b) of the Human Medicines Regulations (HMR) 2012, from the obligation that certain particulars should appear on the outer and immediate packaging of BEROMUN® 1mg and that the information must be given in English .

Call for reporting

Healthcare professionals are asked to report any suspected adverse reactions to the Yellow Card Scheme electronically. Report via the website <https://www.gov.uk/yellowcard>, the free Yellow Card app available from the [Apple App Store](#) or [Google Play Store](#), and some clinical IT systems (EMIS, SystmOne, Vision, MiDatabank) for healthcare professionals. Suspected side effects can also be reported by calling 0800 731 6789 for free.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset timing, treatment dates, and product brand name.



Company contact point

If you have any questions about this letter or require more information about BEROMUN® 1mg, please contact Belpharma s.a at office@belpharma.lu.

Yours faithfully,

Elmira BAJELAN
Clinical and Technical Manager
Belpharma s.a